4.7 Article

Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis

期刊

GUT MICROBES
卷 13, 期 1, 页码 -

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2021.1927633

关键词

Metabolic-dysfunction associated fatty liver disease (MAFLD); Akkermansia muciniphila; L-aspartate; bile acid metabolism; lipid oxidation; gut-liver axis

资金

  1. Key Projects of National Natural Science Foundation of China [81930098]
  2. National Natural Science Foundation of China [21672265, 81872732, 81703336]
  3. Science and Technology Program of Guangzhou [201704020104]
  4. Special Fund for Science and Technology Development in Guangdong Province [2016A020217004]
  5. Natural Science Foundation of Guangdong Province [2017A030308003]
  6. Outstanding Talents of Guangdong Special Plan [2019JC05Y456]
  7. Fundamental Research Funds for the Central Universities [19ykpy132]
  8. Guangdong key areas R D projects [2018B020205002]
  9. Guang Dong Cheung Kong Philanthropy Foundation [E2018096]

向作者/读者索取更多资源

Akkermansia muciniphila has therapeutic potential in treating metabolic disorders such as NAFLD, with mechanisms involving increased mitochondrial oxidation, bile acid metabolism, and reshaping of gut microbiota composition. Additionally, the regulation of L-aspartate metabolism contributes to the beneficial effects on MAFLD.
The gut bacterium Akkermansia muciniphila has been increasingly recognized for its therapeutic potential in treating metabolic disorders, including obesity, diabetes, and metabolicdysfunction-associated fatty liver disease (MAFLD). However, its underlying mechanism involved in its well-known metabolic actions needs further evaluation. The present study explored the therapeutic effect and mechanism of A. muciniphila in intervening MAFLD by using a high-fat and high-cholesterol (HFC) diet induced obese mice model. Mice treated with A. muciniphila efficiently reversed MAFLD in the liver, such as hepatic steatosis, inflammatory, and liver injury. These therapeutic effects persisted after long-term drug withdrawal and were slightly weakened in the antibiotics-treated obese mice. A. muciniphila treatment efficiently increased mitochondrial oxidation and bile acid metabolism in the gut-liver axis, ameliorated oxidative stress-induced cell apoptosis in gut, leading to the reshaping of the gut microbiota composition. These metabolic improvements occurred with increased L-aspartate levels in the liver that transported from the gut. The administration of L-aspartate in vitro or in mice displayed the similar beneficial metabolic effects mentioned above and efficiently ameliorated MAFLD. Together, these data indicate that the anti-MAFLD activity of A. muciniphila correlated with lipid oxidation and improved gut-liver interactions through regulating the metabolism of L-aspartate. A. muciniphila could be a potential agent for clinical intervention in MAFLD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据